Member Info for Drillbits

Last year revenue was �1.64m, an increase of 40% over 2016. I reckon, this year revenue should be in excess of �2.4m (may be �3m with little luck). This should give net profit around �100k. Plus some good news should treble (if not double) the share price. A reasonable educated guess. DYOR.

The stupidity of this board for not expecting Fevertree to take over Distil is incredible.

Marriage between Fevertree & Distil should be match made in heaven.

Fevertree has more than enough funds to acquire 51% of Distil's shares at current price.

Distil and Fevertree should become one. IMO

Share price is down despite company is doing well courtesy of short term traders, it will bounce back in due course.

Can't wait for them to sell.

I am eternal optimist. I reckon revenue should be over £2m and net profit over £50k.

Touchwood, I have been lucky being landlord for over 10 years so far. But my recent tenants have failed to pay May rent as their building contracts have come to an end. I might have to take legal action to evict. Would it be better to use litigation lawyers or organisations like "thelandlordgroup". The litigation lawyers are very expensive and they want money before saying "hello". Through "thelandlordgroup", I can issue section 21 or 8 costing under £100. Court case and bailiff will cost extra £1000. What route did you take oldveryold?

Stock Market is for risk takers. Real Estate is for investors.

Old city adage "speculate to accumulate" works for me.

...and Don Goulding was MD of Diaego (Spain) in 2002. So, my point is nothing is impossible.

"As a company, if you’re looking to invest in spirits or wine, it’s spirits every time". Jack Keenan, President, United Distillers and Vintners, Diageo PLC.

Wrong again in your interpretation GB. At no point I said Diageo owned RedLeg or they are interested in RedLeg. I started my sentence with the year 2002, RedLeg was not around then. Use your brain.

Let me make it clear to dummies. At no point I said Diageo owned RedLeg.

"As a company, if you’re looking to invest in spirits or wine, it’s spirits every time". Jack Keenan, President, United Distillers and Vintners, Diageo PLC. In April 2002, Diageo plc (Diageo) announced its intent to sell its Glen Ellen and MG Vallejo wine subsidiaries to the Wine Group for $83 million. The sale was to include the Glen Ellen and MG Vallejo brand names and all existing inventory but not the vineyards/facilities of the two wineries. Glen Ellen and MG Vallejo wines typically sold for about $5–$7 a bottle. These brands did not fit into Diageo’s increasing emphasis on marketing premium wine brands that sold for $10–$15 a bottle and higher. Wine industry observers viewed the sale of Glen Ellen and MG Vallejo as a move towards brand rationalization, that is, allowing Diageo to concentrate its marketing efforts on a smaller number of more upscale brands like RedLeg Spiced Rum.

Does anyone knows why AZN went down this morning? There was a divestment news but it is a good news.

April 22, 2015 By Riley McDermid, BioSpace.com Breaking News Sr. Editor Rumors are continuing to rumble that British drug giant AstraZeneca PLC (AZN) is likely to receive a second, higher bid for the company from its erstwhile suitor Pfizer Inc. (PFE), almost a year after its first $119 billion offer fell flat on its face last May. Closely followed Motley Fool columnist Alessandro Passetti wrote Wednesday that a senior banker had told him that there are “widespread rumors in the asset management community that Pfizer is considering another bid for Astra.” Passetti said that the value knocked off of Astra’s share price after it refused the bid could make it a manageable target financially, though its possibility as a tax haven has now been revoked after American regulators put the kibosh on so-called inversion deals last year. AstraZeneca ultimately rejected Pfizer’s final bid of 55 pounds per share because it felt its experimental drug company made it a valuable standalone entity. Pfizer had planned to move its headquarters to Ireland as part of the deal, hoping to capitalize on lucrative tax loopholes that have since been closed. “I think that Pfizer won’t make any comeback as tax-driven deals appear to be off the table, so there are two elements you ought to take into account right now: first-quarter results, which are due on Friday, and Astra’s pipeline of drugs,” he wrote. “On the face of it, 2014 quarterly figures are relatively easy to beat, so I would not be surprised if good news surrounded Astra in the wake of the announcement. That may contribute to short-term upside, but it’s hard to believe capital appreciation would be greater than 1 percent to 1.5 percent on the day, regardless of how the market performs.” Unnamed sources also said that upcoming data from the American Society of Clinical Oncology conference for Astra and competitors like Bristol-Myers Squibb, Merck and Roche could clinch Pfizer’s decision to take another bite at the apple.

I hope so...:)

I heard over the grapevine that first quarter results are not looking good. Sales down like for like.